Data on Novartis Skin Cancer Treatment - Analyst Blog
February 20 2014 - 4:50PM
Zacks
Novartis (NVS) announced positive top-line
results from a phase II trial, BOLT (Basal cell carcinoma Outcomes
in LDE225 Trial) on skin cancer candidate LDE225.
We note that Novartis is evaluating LDE225 for the treatment of
advanced basal cell carcinoma.
The BOLT trial is being conducted to assess the safety and
efficacy of two oral dose levels of LDE225 (200 mg and 800 mg) in
patients suffering from locally advanced or metastatic basal cell
carcinoma.
The study met its primary endpoint of achieving an objective
response rate in patients within six months of treatment. The
objective responses include complete response (clinically
significant tumor response with complete absence of disease) and
partial response (clinically significant tumor shrinkage).
We note that Novartis is also evaluating LDE225 for the
treatment of myelofibrosis, leukemia and solid tumors.
We are encouraged by Novartis' efforts to develop various
treatments for cancer. The company recently announced the
acquisition of a privately held biotechnology company, CoStim
Pharmaceuticals Inc.
CoStim Pharma is a biotechnology company, which focuses on
harnessing the immune system to eliminate immune-blocking signals
from cancer.
CoStim Pharma’s acquisition will strengthen Novartis' position
in cancer immunotherapy discovery programs.
The acquisition will add late discovery stage immunotherapy
programs directed to several targets, including PD-1 to Novartis'
pipeline.
We remind investors that Novartis boasts of a strong oncology
portfolio with drugs like Gleevec, Sandostatin SC/Sandostatin LAR,
Afinitor, Exjade, Zometa, Femara and Jakavi among others.
Hence, the development of cancer immunotherapy agents will
further complement the extensive portfolio of drugs.
Novartis currently carries a Zacks Rank #3 (Hold). Some
better-ranked stocks include Shire (SHPG),
Auxilium Pharmaceuticals (AUXL) and Forest
Laboratories (FRX). All these stocks carry a Zacks Rank #1
(Strong Buy).
AUXILIUM PHARMA (AUXL): Free Stock Analysis Report
FOREST LABS A (FRX): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
SHIRE PLC-ADR (SHPG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024